455 related articles for article (PubMed ID: 17245318)
1. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
2. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
3. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
4. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
5. [Novel inhibitors of Bcr-Abl].
Jakubowska J; Czyz M
Postepy Hig Med Dosw (Online); 2006; 60():697-706. PubMed ID: 17245319
[TBL] [Abstract][Full Text] [Related]
6. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
9. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
11. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
12. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
O'Dwyer ME; Druker BJ
Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
[TBL] [Abstract][Full Text] [Related]
13. STI571 (imatinib mesylate): the tale of a targeted therapy.
Thambi P; Sausville EA
Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
15. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
18. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
19. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
20. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA
Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]